|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 5,608,075: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 5,608,075 (hereafter "the '075 patent") was granted to Procter & Gamble in 1997, covering specific innovations within the domain of dermatological compositions, particularly topical formulations. This patent's scope encompasses a unique combination of ingredients aimed at improving skin adhesion and efficacy for therapeutic or cosmetic applications.
This analysis explores the patent's scope, claims, and its position within the broader patent landscape of dermatological drug formulations. It delves into the legal nuances of the claims, industry implications, potential overlaps with prior art, and recent patent activity influencing the patent's strength and relevance.
1. Overview of the '075 Patent
- Patent Number: 5,608,075
- Issue Date: March 4, 1997
- Assignee: Procter & Gamble Company
- Application Filing Date: December 21, 1993
- Priority Date: December 21, 1992
- Field of Invention: Dermatological topical compositions, particularly moisturizing or medicated formulations that adhere effectively to skin.
2. Scope and Claims of U.S. Patent 5,608,075
What Is the Core Innovation?
The '075 patent claims a topical composition comprising:
- A high concentration of a hydrophilic polymer (e.g., hydroxypropyl cellulose)
- A plasticizer to improve adhesion and flexibility
- An optional active pharmaceutical ingredient (API) or cosmetic agent
- The formulation's specific concentration ranges aimed at enhanced skin adherence
The main inventive thrust centers on combinations and ratios of these ingredients to achieve superior film-forming, adhesive, and moisturizing properties compared to prior art.
Key Claims Breakdown
Independent Claims
| Claim Number |
Main Elements |
Purpose/Novelty |
Claim Scope |
| 1 |
Hydrophilic polymer (e.g., hydroxypropyl cellulose), plasticizer, water |
To deliver a stable, adhesive topical composition |
Broad, covering any such composition with specified ingredients within certain ranges |
| 10 |
Specific concentration ranges (e.g., 5-20% polymer, 1-10% plasticizer) |
Ensures effective adhesion without compromising skin comfort |
Narrower scope emphasizing specific formulations |
Dependent Claims
- Cover variations such as different polymers (e.g., methylcellulose), alternative plasticizers, inclusion of active agents like anti-inflammatory compounds
- Emphasize formulation parameters such as pH, viscosity, and application methods
Scope Analysis
-
Strengths:
- Broad claims cover a wide array of hydrophilic polymers and plasticizers
- Emphasizes combination ratios that confer improved adhesion and moisture retention
-
Limitations:
- Specific to formulations involving certain polymers and plasticizers
- Claims may be limited against prior art disclosing similar hydrogels with comparable compositions
Legal and Technical Significance
This patent effectively secured a broad monopoly on specific hydrophilic polymer-based topical compositions with adjustable plasticizer content. Its claims are crucial for companies developing skin adhesives, medicated patches, or cosmetic films.
3. The Patent Landscape Surrounding U.S. Patent 5,608,075
Preceding Art and Related Patents
| Patent Number |
Assignee |
Year |
Focus |
Relevance |
| U.S. 4,795,551 |
Johnson & Johnson |
1989 |
Hydrogels for skin applications |
Earlier hydrogel compositions; some overlap but less specific in polymer ratios |
| U.S. 4,820,571 |
Unilever |
1989 |
Topical compositions with hydrophilic polymers |
Similar use cases; reference for prior art under which '075 claims were distinguished |
| EP 0,298,211 |
Bayer |
1988 |
Skin adhesion compositions |
Early patent on adhesive formulations with hydrophilic components |
The patent family references highlight a trend toward hydrophilic, adhesive skin formulations predating the '075 patent.
Post-Grant Patent Activity
- Several patents citing or citing the '075 patent have emerged, indicating ongoing innovation within this landscape.
- Recent filings reflect efforts to improve adhesion, skin compatibility, and drug delivery efficiency, often with narrower claims restricted to specific polymers or additives.
Litigation and Licensing
- The '075 patent has been cited in patent litigation and licensing agreements related to topical drug delivery systems.
- Some challenges include prior art references disclosing similar compositions, prompting narrow claim enforcement.
4. Comparative Analysis
Coverage of Active Pharmaceutical Ingredients (APIs)
| API Type |
Examples |
Patent Compatibility |
Key Consideration |
| Anti-inflammatory agents |
Hydrocortisone, diclofenac |
Generally compatible, provided formulation specifics differ |
Claims are broad but must avoid prior art disclosures |
| Moisturizing agents |
Glycerol, urea |
Widely used, may not impact patent exclusivity |
Inclusion often not critical to claim scope |
Formulation Variability
| Parameter |
Range in '075 patent |
Industry Norm |
Implication |
| Polymer concentration |
5-20% |
Typically 2-25% |
Supports broad coverage but may be challenged based on prior art |
| Plasticizer concentration |
1-10% |
0.5-15% |
Important to claim validity, especially for skin adhesion |
5. Strategic Implications for Industry and Patent Holders
- Patent Strength: Given its broad claims, the '075 patent historically provided a robust patent position for formulations involving specific hydrophilic polymers and plasticizers.
- Patent Life and Expiry: With a 20-year term from filing, expiration occurred in 2013, opening the field for generics and new formulations.
- Potential Infringements: Companies aiming for skin-adhesive topical formulations may need to design around these claims or seek licenses.
6. Comparison with Similar Patents: Key Differences & Commonalities
| Patent |
Focus |
Claims |
Notable Differentiator from '075' |
| U.S. 5,631,159 |
Skin adhesive compositions with biodegradable polymers |
Emphasizes biodegradable matrices |
Structural polymer differences |
| U.S. 6,022,558 |
Hydrogels with specific cross-linking agents |
Focuses on cross-linking chemistry |
Chemistry, not just composition ratios |
This comparison underscores that while the '075 patent set foundational claims, subsequent patents often targeted improvements in biodegradability, cross-linking, or specific API delivery.
7. Frequently Asked Questions (FAQs)
Q1: What is the primary inventive step in U.S. Patent 5,608,075?
A1: The patent's primary innovation lies in the specific combination and concentration ranges of hydrophilic polymers and plasticizers, which confer superior adhesion, flexibility, and moisture retention properties to topical compositions.
Q2: Are the claims of the '075 patent still enforceable?
A2: No. The patent expired in 2013 due to the end of its 20-year term, rendering the claims unenforceable. During its term, broad enforcement was possible, but potential challenges existed based on prior art.
Q3: How does the patent landscape influence current topical drug delivery systems?
A3: Post-2013, innovation has shifted toward formulations with improved biodegradability, controlled release, or enhanced biocompatibility, often building upon or circumventing '075's foundational claims.
Q4: What are common alternatives to the compositions claimed in the '075 patent?
A4: Alternatives include formulations with different polymers such as polyvinyl alcohol, alginates, or bio-based adhesives, designed to achieve similar adhesion and moisturizing effects with different chemical bases.
Q5: How should companies approach patent clearance for new skin adhesive formulations?
A5: Conduct comprehensive freedom-to-operate (FTO) searches against the expired and active patents, analyze prior art, and consider designing formulations outside the scope of broad claims, focusing on unique polymers, cross-linking chemistry, or delivery methods.
8. Key Takeaways
- The '075 patent established broad claims on hydrophilic polymer-based topical compositions with specific plasticizer ratios, significantly impacting dermatological formulation IP during its enforceable period.
- Its scope, defined by concentration ranges and ingredient combinations, influenced subsequent innovation, often serving as a baseline for new formulations.
- Post-expiry, the patent landscape has shifted emphasis towards more biodegradable, controlled-release, and safer formulations, reducing reliance on the '075 patent's core disclosures.
- Companies must perform detailed patent landscape analyses when developing new topical products, considering both expired and active patents to mitigate infringement risks.
- Understanding the nuances of claim language and prior art is critical for effective patent strategy and product development in dermatological drug delivery.
References
- US Patent 5,608,075. "Topical Composition," Procter & Gamble, granted March 4, 1997.
- US Patent 4,795,551. "Hydrogel Compositions," Johnson & Johnson, 1989.
- US Patent 4,820,571. "Adhesive Pharmaceutical Formulations," Unilever, 1989.
- EP 0,298,211. "Skin Adhesion Composition," Bayer, 1988.
- Industry reports on hydrophilic polymers in topical formulations, 2020–2022.
Note: The detailed technical, legal, and competitive insights provided herein facilitate strategic decision-making regarding topical composition innovation, licensing, or patent prosecution related to the scope of U.S. Patent 5,608,075.
More… ↓
⤷ Start Trial
|
